Posterior segment recurrences in Vogt-Koyanagi-Harada disease
- PMID: 17898934
- DOI: 10.1007/s10792-007-9144-8
Posterior segment recurrences in Vogt-Koyanagi-Harada disease
Abstract
Aim: To describe the clinical profile, management, and outcome in seven patients with posterior segment recurrence in Vogt-Koyanagi-Harada (VKH) disease.
Material and methods: Retrospective chart review of all the patients of VKH disease presenting to our institute between 2001 and 2005 was carried out. Patients with a documented posterior segment recurrence during follow-up were included in this study. Their history, systemic associations, ocular findings, investigations, management strategies, and treatment response were noted.
Results: Out of 82 VKH patients screened, documented posterior segment recurrence was seen in seven patients who included five women and two men, with a mean age of 33.7 years (range 22-55 years). At onset, two patients had incomplete and five had probable VKH disease. At the time of recurrence, four patients were on maintenance dose (5-10 mg/day) of oral corticosteroid while the remaining three were off treatment. The mean interval between the primary episode and posterior segment recurrence was 33.7 weeks (range 16-52 weeks). All posterior segment recurrences were bilateral and were characterized by vitritis (eight eyes), papillitis (14 eyes), multiple yellow-white oval subretinal lesions (six eyes), and exudative retinal detachment (10 eyes). The recurrences were managed with oral corticosteroids (1.0-1.5 mg/day) and Azathioprine (2.0-2.5 mg/day). Subsequently, three patients experienced a second episode of posterior segment recurrence, which also responded to the corticosteroid-Azathioprine combination.
Conclusions: Recurrences in VKH disease may involve predominantly the posterior segment, and respond well to the standard treatment.
Similar articles
-
The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease.Acta Ophthalmol. 2012 Dec;90(8):e603-8. doi: 10.1111/j.1755-3768.2012.02498.x. Epub 2012 Sep 12. Acta Ophthalmol. 2012. PMID: 22971163
-
Vogt-Koyanagi-Harada Disease Presenting as Papillitis vs. Classic Serous Retinal Detachment: A Comparative Analysis of Outcomes.Ocul Immunol Inflamm. 2025 May;33(4):570-577. doi: 10.1080/09273948.2024.2424475. Epub 2024 Nov 8. Ocul Immunol Inflamm. 2025. PMID: 39514788
-
Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.Br J Ophthalmol. 2019 Feb;103(2):274-278. doi: 10.1136/bjophthalmol-2017-311691. Epub 2018 Apr 17. Br J Ophthalmol. 2019. PMID: 29666121
-
Vogt-Koyanagi-Harada disease.Semin Ophthalmol. 2005 Jul-Sep;20(3):183-90. doi: 10.1080/08820530500232126. Semin Ophthalmol. 2005. PMID: 16282153 Review.
-
Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.Ocul Immunol Inflamm. 2019;27(2):229-234. doi: 10.1080/09273948.2017.1373827. Epub 2017 Oct 12. Ocul Immunol Inflamm. 2019. PMID: 29023176 Review.
Cited by
-
Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature.J Ophthalmic Inflamm Infect. 2023 May 19;13(1):27. doi: 10.1186/s12348-023-00333-6. J Ophthalmic Inflamm Infect. 2023. PMID: 37204477 Free PMC article.
-
Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals.Jpn J Ophthalmol. 2015 May;59(3):157-63. doi: 10.1007/s10384-015-0377-1. Epub 2015 Mar 26. Jpn J Ophthalmol. 2015. PMID: 25808016
-
Vogt-Koyanagi-Harada Disease and COVID.J Clin Med. 2023 Sep 27;12(19):6242. doi: 10.3390/jcm12196242. J Clin Med. 2023. PMID: 37834885 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources